Pharma360 Team


David Segarnick Ph.D., Managing Director, heads BERYL China’s Healthcare Division. At Beryl, he is also involved in manager due diligence. He provides Beryl analysts with evaluation pertaining to specific healthcare, pharmaceutical and biotech holdings in hedge funds’ portfolios. Dr. Segarnick has been a medical and marketing authority in healthcare communications and education for more than 20 years. He held senior management and strategic planning positions in industry and academia. He has extensive pharmaceutical pre-launch and launch product development experience in major therapeutic areas.  His specific areas of expertise include anesthesiology, anti-infectives, cardiovascular disease, chronic pain, endocrinology/diabetology, gastroenterology, hematology, men’s health, obstetrics / gynecology, oncology, orthopedics, rheumatology, neurology, and psychiatry.

Dr. Segarnick has worked on many of the major blockbuster product launches over the past two decades. He is the architect of numerous scientific platforms underlying clinical differentiation for pharmaceutical and biotech product introductions worldwide. He trained at the New York University School of Medicine and the New York Veterans Affairs Medical Center.  He was a member of the faculty at the New York University School of Medicine, Bellevue Hospital, and the New York Veterans Administration Medical Center.  He moderates more than 20 advisory board meetings, clinical development workshops and scientific platform development programs each year and provides onsite data surveillance at key international medical congresses. Dr. Segarnick has authored more than a dozen articles in peer-reviewed medical journals and has contributed several chapters in medical textbooks. He currently teaches pharmacology and product development to medical and graduate students at the University of Medicine & Dentistry of New Jersey in Newark.



Zhifeng Long Ph.D. Director, heads BERYL Pharma360 strategic relationships with pharmaceutical and biotech firms. Prior to joining BERYL, Dr. Long founded Personal Diagnostix Inc where he serves as CEO. He brings 24 years of industry experience and a well established network in China to Pharma360 from large international pharmas to innovative biotech companies.  Prior to 2010, he was the founding vice president of AnGes Inc.  During his tenure, AnGes raised $180 million from Tokyo Stock Exchange and received a total of $179 million from Daichi Pharmaceuticals for the co-development of HGF for the treatment of peripheral artery disease (PAD).

Dr. Long has spent 23 years in the pharmaceutical / biotech industry, including Hoffmann-La Roche Inc., Quality Biotech Inc., Genetics Therapy Inc., Sandoz Pharmaceuticals Corp., Novartis Pharmaceuticals Corp., and AnGes Inc.  His previous positions included Director of BioAnalytical Services at Quality Biotech, Director of Molecular Biology Core/Clinical Support Labs at Novartis, VP for Clinical Biosafety and Research, VP for Preclinical Research, and VP for Manufacturing and QC at AnGes Inc. He played a major role in more than 20 clinical trials from phase I to III covering therapeutic areas of cancer, cardiovascular disease, organ and bone marrow transplantation, inflammation, dermatitis, and AIDS in 19 countries.

Dr. Long is a recognized leader in biotech industry, in gene therapy and in cancer drug development.  He has been invited to speak at many international conferences, including FDA sponsored meetings. He has published papers with scientific significance in the journals of Nature Medicine, Nature and Science.  His publications on gene therapy biosafety testing of patients are referenced in the “FDA Guidance to the Industry for Gene and Cellular Therapy”. Dr. Long received his B.Sc. in Genetics in 1982 from Fudan University in Shanghai and his Ph.D. in Genetics in 1987 from Leeds University in England. Dr. Long is the elected president (2011-2012) of the Chinese Biopharmaceutical Association – USA (CBA), a Chinese American pharmaceutical professional organization with over 3000 members in the US and China. 


Tait's Photo

Lance Tait Ph.D. is Medical Writer for Pharma360. Dr. Tait has over twenty years experience in pharmaceutical / healthcare communications. He has excelled in critical analysis, strategic planning, new accounts development, editorial and writing projects, as well as working hand-in-hand with clients when creating digital film and new media promotional and CME presentations. His specialties include all facets of medical meetings and conferences reporting, executive summaries, KOL identification and interviewing, and peer discussion guides.

Dr. Tait has worked within a wide range of therapeutic areas and with a variety of medical conditions. He has worked for a number of major pharmaceutical companies in North America, Europe and Australia including Abbott Laboratories, Burroughs Wellcome, Eli Lilly, Genzyme, GlaxoSmithKline, Roche, Rhone-Poulenc, Sanofi, The Upjohn Company and Wyeth.  He is multilingual (English, French and German) and has been based in New York, Toronto, London and Paris. He studied three years of Mandarin Chinese (reading and writing) while in college and has contacts and consultancy experience in Shanghai. Dr. Tait is an alumnus of Boston University.